Skip to main content
Pharma Equity Group A/S logo

Pharma Equity Group A/S — Investor Relations & Filings

Ticker · BLVIS ISIN · DK0061155009 LEI · 2138008SUI4D917FKN20 CO Financial and insurance activities
Open in API
Filings indexed 1,627 across all filing types
Latest filing 2022-10-04 Proxy Solicitation & In…
Country DK Denmark
Listing CO BLVIS

About Pharma Equity Group A/S

https://bcbsfepvision.com/

Pharma Equity Group A/S is an investment company specializing in early-stage biotechnology, life science, and MedTech companies. The group's mission is to support its portfolio companies in developing novel therapies and effective medicines for unmet medical needs. A primary investment is its subsidiary, Reponex Pharmaceuticals, a clinical-stage biopharmaceutical company focused on developing treatments for serious, acute, and chronic inflammatory diseases. The company is actively expanding its portfolio through strategic acquisitions to support its growth.

Recent filings

Filing Released Lang Actions
Indkaldelse til ekstraordinær generalforsamling i Blue Vision A/S ("Blue Vision"), den 27. oktober 2022, kl. 14.00 hos Accura Advokatpartnerselskab
Proxy Solicitation & Information Statement Classification · 100% confidence The document is a 'Brevstemme' (Postal Vote) form for an extraordinary general meeting of Blue Vision A/S. It provides shareholders with the ability to cast votes on specific agenda items prior to the meeting. This type of document is a standard proxy solicitation material used to request and collect shareholder votes for a meeting, which falls under the Proxy Solicitation & Information Statement category.
2022-10-04 Danish
Indkaldelse til ekstraordinær generalforsamling i Blue Vision A/S ("Blue Vision"), den 27. oktober 2022, kl. 14.00 hos Accura Advokatpartnerselskab
Proxy Solicitation & Information Statement Classification · 100% confidence The document is an official notice ('Indkaldelse') for an Extraordinary General Meeting (EGM) for Blue Vision A/S. It outlines the agenda, voting requirements, and procedures for shareholder participation, including proxy and postal voting forms. This falls under the category of materials sent to shareholders to provide information and request votes for meetings, which is classified as Proxy Solicitation & Information Statement (PSI).
2022-10-04 Danish
Interim / Quarterly Report 2022
Interim / Quarterly Report Classification · 100% confidence The document is titled 'Delårsrapport' (Interim Report) for the period 1 January – 30 June 2022. It contains comprehensive financial statements, including an income statement, balance sheet, cash flow statement, and notes, as well as a management review (Ledelsesberetning). It is not an announcement of a report, but the report itself, and it contains substantive financial data, fitting the definition of an Interim/Quarterly Report (IR). H1 2022
2022-08-31 Danish
Delårsrapport 1. januar – 30. juni 2022
Report Publication Announcement Classification · 95% confidence The document is a short announcement (Selskabsmeddelelse nr. 19) from Blue Vision A/S regarding the publication of their interim report (Delårsrapport) for the period 1 January – 30 June 2022. While it summarizes key financial figures, the document explicitly includes a link to the full report as an 'attached file' (Vedhæftet fil) and is under 6,000 characters. According to the 'Menu vs Meal' rule, this is a Report Publication Announcement (RPA) rather than the interim report itself. H1 2022
2022-08-31 Danish
M&A Activity 2022
M&A Activity Classification · 99% confidence The document is a short announcement (1138 characters) dated May 3, 2021, titled 'Positivt svar fra Reponex Pharmaceuticals A/S på betinget købstilbud' (Positive response from Reponex Pharmaceuticals A/S to a conditional takeover bid). It explicitly mentions the acceptance of a conditional takeover bid by over 95% of shareholders and refers to the process continuing, pending regulatory approval (Finanstilsynet and Nasdaq Copenhagen). This content directly relates to a merger or takeover proposal. Therefore, the appropriate classification is M&A Activity (TAR). It is not an announcement of a report, so RPA/RNS is less specific.
2022-05-04 Danish
M&A Activity 2022
M&A Activity Classification · 99% confidence The document text is a short announcement (1153 characters) from Blue Vision A/S regarding a 'betinget købstilbud' (conditional takeover bid) on Reponex Pharmaceuticals A/S. It specifies the offer period and explicitly states that the full offer document is attached ('Tilbuddet vedlægges i sin helhed') with a link to download the final version. This structure—a brief announcement pointing to a detailed attached document—fits the definition of a Report Publication Announcement (RPA) or a general Regulatory Filing (RNS). Since this concerns a takeover bid, which is a specific corporate action related to mergers and acquisitions, the most appropriate specific category is M&A Activity (TAR). However, the document itself is the *announcement* of the offer, not the detailed offer document or a general regulatory filing. Given the options, 'TAR' (M&A Activity) is the most relevant subject matter, but if the primary function is announcing the availability of the full offer document, 'RPA' might apply. Since the core subject is a takeover bid, TAR is the best fit for the underlying event, even if this specific text is the announcement wrapper. Let's re-evaluate based on the definitions. TAR is for 'merger proposals or takeover bids'. This is a takeover bid announcement. Therefore, TAR is the most specific classification.
2022-04-05 Danish

Browse filings by year

20 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.